Formic Acid

Formic Acid

SCHEMBL4665737

O=CO.O=S(=O)(Nc1ccc(Nc2cc(-c3ccc4c(ccn4CCCN4CCCC4)c3)ncn2)cc1)c1ccc(F)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
HTR6 P50406 4/20 0.42
PKM P14618 1/20 0.41
EGFR P00533 2/20 0.40
ABL1 P00519 2/20 0.39
BCR P11274 2/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
PIK3CA P42336 1/20 0.37
ACP1 P24666 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GSK3B P49841 1/20 0.36
KIT P10721 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4666096 0.93 PAX8 (0.43) LMNAHTR6ACP1GSK3BKIT
Formic Acid SCHEMBL4664367 0.92 ABL1 (0.41) LMNAHTR6ABL1BCRACP1
Formic Acid SCHEMBL4666078 0.91 HTR6 (0.40) LMNAHTR6ABL1BCRMAPK13
Formic Acid SCHEMBL4667364 0.89 HTR6 (0.41) HTR6ABL1BCRACP1
Formic Acid SCHEMBL4666157 0.89 HTR6 (0.41) HTR6ABL1BCRACP1
Formic Acid SCHEMBL4667472 0.88 PAX8 (0.44) LMNAHTR6HSD17B10GSK3BKIT
Formic Acid SCHEMBL4666146 0.88 HTR6 (0.38) HTR6EGFRSMN1; SMN2HSD17B10GSK3B
Formic Acid SCHEMBL4665807 0.87 HTR6 (0.44) LMNAHTR6ABL1BCRSMN1; SMN2
Formic Acid SCHEMBL4666206 0.87 ABL1 (0.41) HTR6PKMABL1BCRGSK3B
Formic Acid SCHEMBL4665752 0.87 HTR6 (0.43) LMNAHTR6ABL1BCRGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 LMNA 4261/4885HTR6 826/4885PKM 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.